CAC 40
7 479,40 -51,32 (-0,68 %) Euro Stoxx 50
4 894,02 -8,58 (-0,18 %) Dow Jones
39 118,86 -45,20 (-0,12 %) EUR/USD
1,0716 +0,0007 (+0,06 %) Gold future
2 336,90 +0,30 (+0,01 %) Bitcoin EUR
57 344,16 +485,35 (+0,85 %)
Eisai Co., Ltd. (4523N.MX)
Eisai Co., Ltd.
4-6-10, Koishikawa
Bunkyo-ku
Tokyo 112-8088
Japan
81 3 3817 3700
https://www.eisai.co.jp
Secteur(s):
Secteur d’activité:
Employés à temps plein: 11 067
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. Haruo Naito | CEO, Representative Corporate Officer & Director | S.O. | S.O. | 1947 |
| Mr. Gary Hendler | Senior VP & President of EMEA Region | S.O. | S.O. | 1966 |
| Dr. Lynn D. Kramer FAAN, M.D. | Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health | S.O. | S.O. | 1950 |
| Ms. Yanhui Feng | Senior Vice President | S.O. | S.O. | 1972 |
| Dr. Nadeem Sarwar Ph.D. | President | S.O. | S.O. | S.O. |
| Mitsuru Shomon | VP & CFO | S.O. | S.O. | S.O. |
| Mr. Yasushi Okada | Representative Corporate Officer, COO, Industry Affairs, China Business & Data Integrity | S.O. | S.O. | 1958 |
| Makoto Hoketsu | VP & Chief Information Officer | S.O. | S.O. | S.O. |
| Mr. Masatomi Akana | Chief Gov. Rel. and IR Officer, SVP of Global Value, Acc., Japan Subs, General, Env. & Safety Aff. | S.O. | S.O. | 1967 |
| Mr. Kenta Takahashi | Executive VP of IP, Internal Audit & Control, General Counsel and Chief Compliance Officer | S.O. | S.O. | 1959 |
Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Eisai Co., Ltd. en date du 1 juin 2024 est 1. Les scores principaux sont Audit : 1; Société : 1; Droits des actionnaires : 7; Compensation : 1.
